Assenagon Asset Management S.A. Acquires New Shares in AC Immune $ACIU

Assenagon Asset Management S.A. bought a new stake in AC Immune (NASDAQ:ACIU) during the 3rd quarter, Holdings Channel reports. The fund bought 189,892 shares of the company’s stock, valued at approximately $549,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sei Investments Co. acquired a new position in shares of AC Immune during the 2nd quarter worth about $51,000. Acadian Asset Management LLC raised its position in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after acquiring an additional 172,796 shares during the period. Finally, BVF Inc. IL boosted its stake in AC Immune by 1.5% during the 1st quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock worth $37,068,000 after acquiring an additional 300,000 shares during the last quarter. Institutional investors own 51.36% of the company’s stock.

AC Immune Trading Down 1.4%

Shares of NASDAQ ACIU opened at $3.11 on Friday. The company has a fifty day moving average price of $3.10 and a 200 day moving average price of $2.61. The firm has a market cap of $311.77 million, a PE ratio of -3.70 and a beta of 1.60. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.00.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $0.81 million. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%. Equities research analysts forecast that AC Immune will post -0.62 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on ACIU. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Tuesday, November 4th. Zacks Research raised shares of AC Immune from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.